<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2947224/" ref="ordinalpos=1957&amp;ncbi_uid=2501279&amp;link_uid=PMC2947224" image-link="/pmc/articles/PMC2947224/figure/F1/" class="imagepopup">Figure 1. Effects on viability and <span class="highlight" style="background-color:">signaling</span> in MPN mutant cell lines treated with                   PU-H71..  From: HSP90 is a therapeutic target in JAK2-dependent myeloproliferative                neoplasms in mice and humans. </a></div><br /><div class="p4l_captionBody">(<b>A</b>) Cells bearing mutations that result in constitutive activation of                   the JAK-STAT signaling pathway (JAK2V617F [V617F] and MPLW515L [W515L]) have a                   lower IC50 compared with that of Ba/F3 cells bearing BCR-Abl.                   Similarly, UKE-1 cells bearing JAK2V617F are more growth inhibited by PU-H71 than                   either KU812 (BCR-ABL) or THP-1 (JAK2 wild-type [JAK2WT]). (<b>B</b>)                   Western blots reveal a dose-dependent downmodulation of JAK2 and signaling                   intermediates in the JAK-STAT pathway after treatment with PU-H71 for 16 hours in                   Ba/F3 isogenic cell lines. </div></div>